Clinical Trial Update: Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small cell lung cancer has completed, with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• ERBITUX (cetuximab)
• Taxotere (docetaxel)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2012-10-15